Medeon Biodesign, Inc. (TPEX: 6499)
Taiwan
· Delayed Price · Currency is TWD 42.80
-0.25 (-0.58%)
Sep 10, 2024, 1:30 PM CST
Medeon Biodesign Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 211.86 | 196.26 | 298.32 | 68.96 | 123.06 | 453.76 | Upgrade
|
| Revenue Growth (YoY) | 22.12% | -34.21% | 332.61% | -43.96% | -72.88% | -32.63% | Upgrade
|
| Cost of Revenue | 193.79 | 181.89 | 111.51 | 40.33 | 76.75 | 267.52 | Upgrade
|
| Gross Profit | 18.08 | 14.38 | 186.81 | 28.63 | 46.3 | 186.24 | Upgrade
|
| Selling, General & Admin | 183.58 | 185.91 | 153.03 | 108.35 | 98.5 | 141.99 | Upgrade
|
| Research & Development | 715.05 | 667.46 | 521.62 | 415.87 | 289.94 | 300.95 | Upgrade
|
| Operating Expenses | 901.51 | 853.94 | 674.65 | 524.22 | 388.05 | 443.54 | Upgrade
|
| Operating Income | -883.43 | -839.57 | -487.84 | -495.59 | -341.75 | -257.29 | Upgrade
|
| Interest Expense | -6.15 | -6.64 | -5.21 | -1.03 | -1.39 | -2.74 | Upgrade
|
| Interest & Investment Income | 25.05 | 19.94 | 10.29 | 6.12 | 9.61 | 17.64 | Upgrade
|
| Earnings From Equity Investments | - | 13.54 | 47.69 | 19.66 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 7.43 | -6.19 | 15.35 | - | - | -14.41 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.36 | 0.39 | 0.34 | -43.07 | -8.59 | 2.77 | Upgrade
|
| EBT Excluding Unusual Items | -856.73 | -818.53 | -419.38 | -513.91 | -342.12 | -254.03 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.61 | -399.15 | -19.73 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -5.76 | -13.01 | - | - | - | -0.04 | Upgrade
|
| Pretax Income | -864.11 | -1,231 | -439.12 | -513.91 | -342.12 | -254.07 | Upgrade
|
| Income Tax Expense | 8.91 | 39.29 | 57.79 | 72.46 | 5.28 | 28.65 | Upgrade
|
| Earnings From Continuing Operations | -873.02 | -1,270 | -496.9 | -586.36 | -347.4 | -282.72 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | 2,618 | 177.81 | - | Upgrade
|
| Net Income to Company | -873.02 | -1,270 | -496.9 | 2,031 | -169.59 | -282.72 | Upgrade
|
| Minority Interest in Earnings | 62.39 | 65.36 | 63.14 | 46.75 | -23.15 | 20.74 | Upgrade
|
| Net Income | -810.63 | -1,205 | -433.76 | 2,078 | -192.74 | -261.99 | Upgrade
|
| Net Income to Common | -810.63 | -1,205 | -433.76 | 2,078 | -192.74 | -261.99 | Upgrade
|
| Shares Outstanding (Basic) | 92 | 92 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 92 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Change (YoY) | 0.06% | 0.02% | -0.07% | 0.48% | 0.05% | 14.46% | Upgrade
|
| EPS (Basic) | -8.80 | -13.09 | -4.71 | 22.65 | -2.10 | -2.86 | Upgrade
|
| EPS (Diluted) | -8.81 | -13.09 | -4.71 | 22.65 | -2.10 | -2.86 | Upgrade
|
| Free Cash Flow | -874.11 | -810.36 | -601.91 | -301.69 | -171.44 | -290.89 | Upgrade
|
| Free Cash Flow Per Share | -9.49 | -8.80 | -6.54 | -3.28 | -1.87 | -3.18 | Upgrade
|
| Dividend Per Share | - | - | 0.476 | 0.794 | - | - | Upgrade
|
| Dividend Growth | - | - | -40.00% | - | - | - | Upgrade
|
| Gross Margin | 8.53% | 7.33% | 62.62% | 41.52% | 37.63% | 41.04% | Upgrade
|
| Operating Margin | -416.98% | -427.78% | -163.53% | -718.69% | -277.72% | -56.70% | Upgrade
|
| Profit Margin | -382.62% | -613.78% | -145.40% | 3013.75% | -156.62% | -57.74% | Upgrade
|
| Free Cash Flow Margin | -412.58% | -412.90% | -201.77% | -437.51% | -139.32% | -64.11% | Upgrade
|
| EBITDA | -840.48 | -797.3 | -459.64 | -463.09 | -284.45 | -202.12 | Upgrade
|
| EBITDA Margin | - | - | -154.08% | - | -231.16% | -44.54% | Upgrade
|
| D&A For EBITDA | 42.95 | 42.26 | 28.2 | 32.5 | 57.3 | 55.17 | Upgrade
|
| EBIT | -883.43 | -839.57 | -487.84 | -495.59 | -341.75 | -257.29 | Upgrade
|
| EBIT Margin | - | - | -163.53% | - | -277.72% | -56.70% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.